<https://rdf.molmedb.upol.cz/reference/ref4257> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM495082>,
		<https://identifiers.org/molmedb/MM495068>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.0c00075"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/pmid> "32410449"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM495075>;
	<http://purl.org/dc/terms/bibliographicCitation> "Clegg MA, Bamborough P, Chung CW, Craggs PD, Gordon L, Grandi P, Leveridge M, Lindon M, Liwicki GM, Michon AM, Molnar J, Rioja I, Soden PE, Theodoulou NH, Werner T, Tomkinson NCO, Prinjha RK, Humphreys PG.: Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. J Med Chem, Volume 63 (11), 2020"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method30>,
		<https://rdf.molmedb.upol.cz/interaction/membrane18> .
<https://rdf.molmedb.upol.cz/interaction/int1021367> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4257> .
<https://rdf.molmedb.upol.cz/interaction/int1021360> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4257> .
<https://rdf.molmedb.upol.cz/interaction/int1021374> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4257> .